Advertisement
Screener

INVIVYD, INC. (IVVD) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

INVIVYD, INC. Increase Decrease In Operating Lease Liability

INVIVYD, INC. (IVVD) reported Increase Decrease In Operating Lease Liability of -$532.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13

  • INVIVYD, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$235.00K.
  • INVIVYD, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$297.00K.
  • INVIVYD, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$182.00K.
  • INVIVYD, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$289.00K.
  • INVIVYD, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.22M.
  • INVIVYD, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.66M.
  • INVIVYD, INC. increase decrease in operating lease liability for fiscal 2023 was -$1.56M.
  • INVIVYD, INC. increase decrease in operating lease liability for fiscal 2022 was -$475.00K.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 9 month as first filedIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$235.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$532.00K
10-Q · filed 2026-08-13
-$714.00K
derived: sum of 3 quarters · filed 2026-08-13
-$1.00M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$297.00K
10-Q · filed 2026-05-14
-$479.00K
derived: sum of 2 quarters · filed 2026-05-14
-$768.00K
derived: sum of 3 quarters · filed 2026-05-14
-$1.10M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$182.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$471.00K
derived: sum of 2 quarters · filed 2026-03-05
-$808.00K
derived: sum of 3 quarters · filed 2026-08-13
-$1.22M
10-K · filed 2026-03-05
2025-09-30-$289.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$626.00K
derived: sum of 2 quarters · filed 2026-08-13
-$1.04M
10-Q · filed 2025-11-06
-$1.45M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$337.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$747.00K
10-Q · filed 2026-08-13
-$1.16M
derived: sum of 3 quarters · filed 2026-08-13
-$1.58M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$410.00K
10-Q · filed 2026-05-14
-$826.00K
derived: sum of 2 quarters · filed 2026-05-14
-$1.25M
derived: sum of 3 quarters · filed 2026-05-14
-$1.67M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$416.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$838.00K
derived: sum of 2 quarters · filed 2026-03-05
-$1.26M
derived: sum of 3 quarters · filed 2026-03-05
-$1.66M
10-K · filed 2026-03-05
2024-09-30-$422.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$841.00K
derived: sum of 2 quarters · filed 2025-11-06
-$1.25M
10-Q · filed 2025-11-06
-$1.65M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$419.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$825.00K
10-Q · filed 2025-08-14
-$1.23M
derived: sum of 3 quarters · filed 2025-08-14
-$1.62M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$406.00K
10-Q · filed 2025-05-15
-$806.00K
derived: sum of 2 quarters · filed 2025-05-15
-$1.20M
derived: sum of 3 quarters · filed 2025-05-15
-$1.58M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$400.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$792.00K
derived: sum of 2 quarters · filed 2025-03-20
-$1.18M
derived: sum of 3 quarters · filed 2025-03-20
-$1.56M
10-K · filed 2025-03-20
2023-09-30-$392.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$778.00K
derived: sum of 2 quarters · filed 2024-11-14
-$1.16M
10-Q · filed 2024-11-14
-$1.86M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$386.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$767.00K
10-Q · filed 2024-08-14
-$1.46M
derived: sum of 3 quarters · filed 2024-08-14
-$1.03M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$381.00K
10-Q · filed 2024-05-09
-$1.08M
derived: sum of 2 quarters · filed 2024-05-09
-$642.00K
derived: sum of 3 quarters · filed 2024-05-09
-$787.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$697.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$261.00K
derived: sum of 2 quarters · filed 2024-03-28
-$406.00K
derived: sum of 3 quarters · filed 2024-03-28
-$475.00K
10-K · filed 2024-03-28
2022-09-30$436.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$291.00K
derived: sum of 2 quarters · filed 2023-11-09
$222.00K
10-Q · filed 2023-11-09
-$222.00K
10-Q · filed 2022-11-10
$222.00K
derived: sum of 4 quarters · filed 2024-02-09
2022-06-30-$145.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$214.00K
10-Q · filed 2023-08-10
-$214.00K
derived: sum of 3 quarters · filed 2024-02-09
-$214.00K
derived: sum of 4 quarters · filed 2024-02-09
2022-03-31-$69.00K
10-Q · filed 2023-05-11
-$69.00K
derived: sum of 2 quarters · filed 2024-02-09
-$69.00K
derived: sum of 3 quarters · filed 2024-02-09
-$69.00K
derived: sum of 4 quarters · filed 2024-02-09
2021-12-31$0.00
derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09
$0.00
derived: sum of 2 quarters · filed 2024-02-09
$0.00
derived: sum of 3 quarters · filed 2024-02-09
$0.00
8-K · filed 2024-02-09
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$0.00
10-Q · filed 2022-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$0.00
10-Q · filed 2022-08-15
2021-03-31$0.00
10-Q · filed 2022-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49